<DOC>
	<DOCNO>NCT00899977</DOCNO>
	<brief_summary>A pilot study subject refractory hypertension ( 3 concomitant agent SBP &gt; 140 mmHg DBP &gt; 90 mmHg ) randomize double-blind fashion receive 4 single escalate dos study medication clinic .</brief_summary>
	<brief_title>TC-5214 Augmentation Therapy Patients With Refractory Hypertension</brief_title>
	<detailed_description>12 subject refractory hypertension randomize double-blind fashion receive single escalating dos study medication in-clinic : Day 1 ( 1mg ) , Day 8 ( 2mg ) , Day 15 ( 4mg ) Day 22 ( 8mg ) . On 4 day , 10 subject receive TC-5214 , 2 subject receive placebo . Placebo treatment pool across 4 day single-dose produce equivalent reference cohort ( n = 8 ) treatment dose ( n=10 ) . Following single-dose administration 8mg clinic Day 22 , subject continue two week ( Days 23 - 35 ) outpatient self-administration TC-5214 ( 4mg BID ; n = 6 ) , match placebo ( BID ; n = 6 ) . On Day 36 , subject return final in-clinic dose either TC-5214 ( 4mg , n = 6 ) placebo ( n = 6 ) . There 1-week follow-up period end treatment period .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<criteria>1 . Refractory hypertension , define SBP &gt; 140mmHg DBP &gt; 90mmHg , stable dos least 3 concomitant antihypertensive treatment ( must include diuretic ACEI , ARB RA ) 8 week prior Screening . All approve antihypertensive treatment allow except alphaadrenergic blocker , hydralazine , clonidine , guanethidine , guanadrel , rauwolfia alkaloid . 2 . Stable hypertension , define : a. mean SBP Day 7 within 20mmHg mean SBP Day 1 , mean SBPs &gt; 140mmHg ; b. mean DBP Day 7 within 10mm mean DBP Day 1 , mean DBPs &gt; 90mmHg . 3 . Outpatient stable housing . 4 . Subjects must able stay clinic 8 hrs Day 1 , Day 8 , Day 15 , Day 22 , Day 36 . 5 . Able give sign inform consent . 1 . Any unstable medical condition hypertension ; 2 . Stage 3 hypertension ( SBP &gt; 180mmHg and/or DBP &gt; 110mmHg ) ; 3 . Heart rate &gt; 100 beat per minute ; 4 . WOCBP pregnant planning become pregnant study ; 5 . History within past year alcohol illicit drug abuse ; 6 . Unable comply study procedure opinion investigator ; 7 . Concomitant medication medical condition uncontrolled 2 week prior study entry ; 8 . Current use alphaadrenergic blocker , hydralazine , clonidine , guanethidine , guanadrel , rauwolfia alkaloid ; 9 . History myocardial infarction angina pectoris ; 10 . Current seizure disorder ; 11 . Renal insufficiency define serum creatinine &gt; 2.0 ; 12 . Uncontrolled hypothyroidism , vitamin B12 folic acid deficiency ; 13 . History concurrent ileus , glaucoma , urinary retention ; 14 . Inability subject understand sign ICF ; 15 . Known systemic infection ( HBV , HCV , HIV , TB ) ; 16 . Current use smoking cessation therapy within 4 week screen ; 17 . Use herbal supplement ; 18 . Clinically significant find physical exam ; 19 . Clinically significant laboratory ECG abnormality , include QTcF &gt; 460 msec ; 20 . Participation another clinical trial last month ; 21 . Body Mass Index ( BMI ) &gt; 35 . 22 . Body weight &lt; 100 pound . 23 . Site staff family member study site staff .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>refractory hypertension</keyword>
	<keyword>hypertension</keyword>
</DOC>